Maxim Group has $135.0 Target on GW Pharma (NASDAQ:GWPH) after Initiated Coverage

Share with your friends










Submit

London GW Pharma NASDAQ:GWPH

GW Pharma (NASDAQ:GWPH) Price Target & New Coverage by Maxim Group

In an analyst report issued to investors and clients on Friday morning, stock analysts at Maxim Group started coverage on shares of GW Pharma (NASDAQ:GWPH). The firm set a Buy rating with $135.0, giving 16.56 % to target.

After the new coverage NASDAQ:GWPH is currently trading -0.32% lower at $115.82 as of 10:07 PM New York time. GW Pharma’s stock is 0% in the past 200 days. It has underperformed the S&P 500 Index, which has surged 12.80% in the same time.

According to data compiled by Thomson Reuters, GW Pharma (NASDAQ:GWPH)’s stock is covered by 8 equity analysts across the Street, with 0 analysts giving it a Sell rating, 7 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $139.75, which reflects an upside potential of 20.66% over the current price.

GWPH Stock Chart

GW Pharma (NASDAQ:GWPH) Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS).

GW Pharma (NASDAQ:GWPH) traded down -0.32% on 21 April, hitting $115.82. A total of shares of the company’s stock traded hands. This is down from average of 260,866 shares. GW Pharma has a 52 week low of $74.05 and a 52 week high of $137.88. The company has a market cap of $2.87 billion and a P/E ratio of 0.

Get the latest GW Pharma (NASDAQ:GWPH) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.